Annual report [Section 13 and 15(d), not S-K Item 405]

Significant Strategic Collaborations (Details Narrative)

v3.25.4
Significant Strategic Collaborations (Details Narrative) - USD ($)
 12 Months Ended 24 Months Ended 33 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2025
Mar. 01, 2026
Nov. 01, 2025
May 01, 2025
Nov. 01, 2024
Mar. 17, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Revenue $ 2,976,411 $ 2,500,284              
Research and development expenses 3,065,484 3,288,332              
Prepaid expenses and other current assets 166,294 421,954 $ 166,294 $ 166,294          
Accrued expenses and other current liabilities $ 709,916 $ 610,648 $ 709,916 $ 709,916          
Pharmsynthez [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Percent ownership in Xenetic 2.30% 3.40% 2.30% 2.30%          
Takeda [Member] | Royalty Revenue [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Revenue $ 3,000,000 $ 2,500,000              
Catalent Pharma Solutions [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development expenses 2,900,000                
Prepaid expenses and other current assets 53,000 28,000 $ 53,000 $ 53,000          
Accrued expenses and other current liabilities 100,000 100,000 100,000 100,000          
Other assets 300,000 300,000 300,000 300,000          
Scripps Research [Member] | D Nase Technology [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contractual obligation                 $ 900,000
Contractual obligation addition           $ 300,000 $ 400,000 $ 400,000  
Scripps Research [Member] | D Nase Technology [Member] | Subsequent Event [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contractual obligation addition         $ 500,000        
Scripps Research [Member] | Scripps Agreement [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development expenses       1,800,000          
Accrued expenses and other current liabilities 200,000   200,000 200,000          
University Of Virginia [Member] | U V A Agreement [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development expenses     500,000            
Prepaid expenses and other current assets   $ 100,000              
Accrued expenses and other current liabilities $ 31,000   $ 31,000 $ 31,000